Taken together, we have successfully established a human SMN2 reporter for future drug discovery and identified the potential therapeutic value of cysteine protease inhibitors in treating SMA via stabilizing SMN proteins. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.